Angiotensin‐(1–9) attenuates diabetic cardiomyopathy by improving insulin resistance
British Journal of Pharmacology · 2026-06 · 183 (11) · 3032-3048
DOI: 10.1111/bph.70356 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 20.02.2026. Verfasst von Ignacio Norambuena-Soto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Cancer Metabolism, Beckman Research Institute of the City of Hope, Duarte, California, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Diabetic Cardiomyopathies, Peptide Fragments, Angiotensin I. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: American Diabetes Association, Agencia Nacional de Investigación y Desarrollo, FONDECYT postdoctoral fellowship.
Abstract (Originalsprache)
Background and Purpose Diabetic cardiomyopathy is a clinical condition of ventricular dysfunction, with obesity and insulin resistance as the primary risk factors. Under this condition, the heart encounters lipotoxicity, which impairs cardiac insulin sensitivity and leads to cardiomyopathy. Angiotensin‐(1–9) is a peptide of the counter‐regulatory axis of the renin‐angiotensin system with cardioprotective effects. However, its role in diabetic cardiomyopathy is unknown. Experimental Approach To investigate the role of angiotensin‐(1–9), we first induced lipotoxic stress in the heart by high‐fat diet (HFD) feeding in mice. Angiotensin‐(1–9) was then administered for 4 weeks using osmotic mini‐pumps. Cardiac function was assessed, and insulin sensitivity was evaluated in heart tissues after insulin bolus injection. Moreover, lipotoxic stress in vitro was modelled by high glucose medium plus palmitate in neonatal rat ventricular myocytes (NRVMs). Key Results Angiotensin‐(1–9) improves myocardial function and reverts pathological cardiac remodelling under HFD feeding in mice. Moreover, angiotensin‐(1–9) enhances whole‐body glucose tolerance and reduces homeostatic model assessment of insulin resistance (HOMA‐IR). We demonstrate that angiotensin‐(1–9) increases insulin sensitivity in the heart and skeletal muscle but not in adipose tissue or the liver. Mechanistically, angiotensin‐(1–9) does not affect insulin signalling in cardiomyocytes at baseline, whereas it significantly improves insulin action under lipotoxic stress through AT 2 receptors and protein kinase A. Conclusion and Implications These findings demonstrate that angiotensin‐(1–9) improves cardiac function under metabolic challenge and promotes insulin signalling in cardiomyocytes under lipotoxicity, which may shed light on the therapeutic exploration against diabetic cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes and Cancer Metabolism, Beckman Research Institute of the City of Hope, Duarte, California, USA.
- Advanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Químicas y Farmacéuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile.
- State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Ganzhou, Jiangxi, China.
- Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, Jiangxi, China.
- Centro de Modelamiento Molecular, Biofísica y Bioinformática (CM2B2), Facultad Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
- Department of Biochemistry & Molecular Biology, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
ORCID-Profile: Ignacio Norambuena-Soto, Pengfei Zhang, Yin Wang, Ling Fu, Danica Jimenez-Gallegos, Yunqiu Jiang, Hongliang Li, Mario Chiong, Gerald Zapata-Torres, Yingfeng Deng, Marcelo J Kogan, Zhao V Wang, Sergio Lavandero
Förderung
- American Diabetes Association
- Agencia Nacional de Investigación y Desarrollo
- FONDECYT postdoctoral fellowship
- FONDAP
- FONDAP Apoyo
- FONDECYT
- American Heart Association
- Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute of the City of Hope
Zitieren
APA
Norambuena-Soto, I., Zhang, P., Wang, Y., Fu, L., Jimenez-Gallegos, D., Jiang, Y., Yuan, V., Li, H., Chiong, M., Zapata-Torres, G., Deng, Y., Kogan, M. J., Wang, Z. V., & Lavandero, S. (2026). Angiotensin‐(1–9) attenuates diabetic cardiomyopathy by improving insulin resistance. British Journal of Pharmacology, 183(11), 3032-3048. https://doi.org/10.1111/bph.70356
Vancouver
Norambuena-Soto I, Zhang P, Wang Y, Fu L, Jimenez-Gallegos D, Jiang Y, et al. Angiotensin‐(1–9) attenuates diabetic cardiomyopathy by improving insulin resistance. British Journal of Pharmacology. 2026;183(11):3032-3048. doi:10.1111/bph.70356
BibTeX
@article{NorambuenaSoto2026,
author = {Norambuena-Soto, Ignacio and Zhang, Pengfei and Wang, Yin and Fu, Ling and Jimenez-Gallegos, Danica and Jiang, Yunqiu and Yuan, Vivian and Li, Hongliang and Chiong, Mario and Zapata-Torres, Gerald and Deng, Yingfeng and Kogan, Marcelo J and Wang, Zhao V and Lavandero, Sergio},
title = {Angiotensin‐(1–9) attenuates diabetic cardiomyopathy by improving insulin resistance},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {11},
pages = {3032--3048},
doi = {10.1111/bph.70356}
}
EUVIMED